Previous Article | Next Article 
J Virol, July 1998, p. 5366-5372, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Characterization of the Cytolytic T-Lymphocyte
Response to a Candidate Vaccine Strain of Equine Herpesvirus 1 in
CBA Mice
Patrick M.
Smith,
Yunfei
Zhang,
Stephen R.
Jennings, and
Dennis J.
O'Callaghan*
Department of Microbiology and Immunology,
Louisiana State University Medical Center, Shreveport, Louisiana 71130
Received 26 January 1998/Accepted 24 March 1998
 |
ABSTRACT |
The cytolytic T-lymphocyte (CTL) response to respiratory infection
with equine herpesvirus 1 (EHV-1) in CBA (H-2k)
mice was investigated. Intranasal (i.n.) inoculation of mice with the
attenuated EHV-1 strain KyA resulted in the generation of a primary
virus-specific CTL response in the draining mediastinal lymph nodes 5 days following infection. EHV-1-specific CTL could be restimulated from
the spleen up to 26 weeks after the resolution of infection, indicating
that a long-lived memory CTL population was generated. Depletion of
CD8+ T cells by treatment with antibody and complement
prior to assay eliminated CTL activity from both primary and memory
populations, indicating that cytolytic activity in this model was
mediated by class I major histocompatibility complex-restricted,
CD8+ T cells. A single i.n. inoculation with KyA induced
protective immunity against infection with the pathogenic EHV-1 strain,
RacL11. The adoptive transfer of splenocytes from KyA-immune donors
into sublethally irradiated recipients resulted in a greater than
250-fold reduction in RacL11 in the lung. The elimination of both
CD4+ and CD8+ T cells from the transferred
cells abrogated clearance of RacL11, while the selective depletion of
either subpopulation alone had little effect. These results suggested
that both lymphocyte subpopulations contribute to viral clearance, with
either subpopulation alone being sufficient.
 |
INTRODUCTION |
Equine herpesvirus 1 (EHV-1) is a
prevalent respiratory pathogen of horses worldwide (8, 17,
38). Infection of horses with EHV-1 results in fever, respiratory
distress, abortagenic disease, and severe neurological sequelae
(3, 13, 27, 35, 36). The highly contagious respiratory
transmission of EHV-1 has resulted in disastrous outbreaks of disease
in domestic horse populations and has had a significant economic impact
on the equine industry. EHV-1 infection of the horse results in the
generation of a short-lived humoral response but does not confer
long-term protection, as disease often occurs following natural
infection (10, 22). Although both live and inactivated
vaccines are currently available for EHV-1, only relatively short-lived
protection has been observed (11, 12, 24). Furthermore, it
is not clear which immune functions are responsible for conferring the
short-lived protection following vaccination. In addition to specific
antibody responses, peripheral blood leukocytes from vaccinated horses produce gamma interferon in culture (19). EHV-1-specific,
CD8+ class I major histocompatibility complex
(MHC)-restricted cytotoxic T lymphocytes (CTL) have been identified in
peripheral blood mononuclear cells, reaching maximal levels 2 to 3 weeks postinfection (p.i.) (4, 20). However, the
effectiveness of the current vaccines in stimulating EHV-1-specific CTL
and their role in protective immunity in vivo are currently not known.
Horses inoculated with the attenuated EHV-1 strain Kentucky A (KyA)
exhibited a reduction in clinical signs following challenge with a
pathogenic EHV-1 strain (33, 34). Although the attenuated strain induced a protective response, in terms of a reduced duration of
viral shedding and viremia, the ability of this strain to induce an
EHV-1-specific antibody response was weaker than that of the virulent
strain. This finding suggested that immune functions other than the
generation of specific antibodies might be critical in the resolution
of infection. To generate a more effective EHV-1 vaccine, a better
understanding of the precise immune functions associated with
protection and resolution from EHV-1 infection is essential.
A murine model of respiratory EHV-1 infection which closely mimicked
EHV-1 infection in the natural host was established in various strains
of mice (5). Common features included replication in the
respiratory mucosae, the development of pneumonitis, cell-associated viremia, and abortion (5, 6). Specific immune responses are
important for modulating infection. In the mouse, the passive transfer
of hyperimmune polyclonal rabbit EHV-1-specific antibodies into
infected mice significantly reduced the viremia following challenge
with live EHV-1 (5). Subsequent studies demonstrated that
various EHV-1 glycoproteins, including gB, gC, gD and gH, were capable
of inducing the generation of neutralizing antibodies (9, 23, 40,
49, 52, 56). Furthermore, inoculation of mice with gB, gC, and/or
gD elicited a protective response against subsequent challenge with
pathogenic EHV-1 (39, 49, 50, 52, 56). However, each of
these EHV-1 gene products is capable of eliciting both B- and T-cell
responses; thus, the role of distinct immune functions conferring
protection is not clearly defined.
In the most extensively studied BALB/c mouse model of EHV-1 infection,
adoptive transfer experiments demonstrated that immune spleen cells
isolated from mice primed with live, but not heat-killed, EHV-1 reduced
viral levels in both the lungs and nasal turbinates of infected
recipient mice (5). Although the specific cell population
responsible for protection was not determined, the data suggested that
cell-mediated immune functions may be critical in the resolution of
EHV-1 infection. The adoptive transfer of defined T-cell subpopulations
demonstrated that both CD4+ and CD8+ T cells
play a role in controlling EHV-1 respiratory infection. The
CD8+ T-cell subpopulation appeared to play a more dominant
role, although the functions by which protection was mediated were not
defined (7). If the immune response was elicited by
immunization with recombinant baculovirus-derived EHV-1
glycoproteins, the response was altered so that CD4+ T
cells were predominantly associated with protection (52). Thus, either T-cell subpopulation is likely to play an important role
in the optimal response to infection.
While adoptive transfer studies have implicated an important role for
CD8+ T cells in the control of EHV-1 infection in the lungs
of BALB/c mice (7), there has been no direct assessment of
CD8+ T-cell effector functions in this model. This is due
predominantly to the lack of suitable class I MHC-compatible,
H-2d-expressing murine cells that are
susceptible to infection with EHV-1. However, the attenuated KyA strain
of EHV-1 has been propagated in our laboratory in suspension cultures
of murine L-M fibroblasts that express the H-2k
haplotype. Therefore, an alternative mouse model, using mice expressing
the H-2k haplotype, was adopted principally to
assess the activation of EHV-1-specific CTL responses. Initial studies
by Awan et al. (5) demonstrated that CBA
(H-2k) mice were susceptible to infection with
EHV-1 strain Ab4. In the present study, CBA mice were susceptible to
respiratory tract infection by both the nonpathogenic KyA and the
pathogenic RacL11 strains of EHV-1. Furthermore, infection of CBA mice
with the attenuated KyA strain generated a vigorous CD8+,
class I MHC-restricted, EHV-1-specific primary CTL response in the
draining mediastinal lymph nodes (MLN) and a long-term memory CTL
response in the spleen. These studies provide the basis for a model
system to analyze the potential importance of class I MHC-restricted
CTL activity in controlling EHV-1 infection in vivo.
 |
MATERIALS AND METHODS |
Virus and cell culture.
The Kentucky A KyA strain was
propagated in suspension cultures of L-M mouse fibroblasts as
previously described (41). EHV-1 strain RacL11, a kind gift
of Anton Mayr, Institute for Medical Microbiology, Infectious and
Epidemic Diseases, Ludwig-Maximilian-University, Munich, Germany, was
grown in NBL6 equine dermal cells (American Type Culture Collection).
Titers of both viruses were determined on rabbit kidney cells (ATCC
RK-13). L-M, NBL6, and RK cell lines were maintained at 37°C in
Eagle's minimal essential medium supplemented with penicillin (100 U
per ml), streptomycin (100 µg per ml), nonessential amino acids, and
5% fetal calf serum (FCS). For suspension cultures, L-M fibroblasts
were maintained at 37°C in Eagle's minimal essential medium
supplemented with yeast extract-lactalbumin hydrolysate-peptone, antibiotics, and 5% FCS (41).
Mice.
Female CBA (H-2k) mice, 3 to 6 weeks of age, were obtained from Harlan Sprague Dawley, Indianapolis,
Ind., or Jackson Laboratory Bar Harbor, Maine. Mice were maintained in
the Animal Resource Facility of the Louisiana State University Medical
Center, Shreveport, in cages equipped with filter tops. All mice were
rested for a minimum of 1 week prior to use.
Infection and assessment of CTL activity.
Mice were
anesthetized with Halothane (Sigma Chemical Co., St. Louis, Mo.) and
inoculated intranasally (i.n.) with 2 × 106 PFU of
EHV-1 KyA in a volume of 50 µl. To assess primary CTL responses,
lymphocytes were isolated from the MLN or superficial cervical lymph
nodes (CLN) 5 days postinoculation, and a single-cell suspension was
obtained by pressing the lymphoid tissues through a 60-gauge wire mesh
screen. The lymphocytes were washed and cultured (107 cells
per well) for 3 days at 37°C and 5% CO2 in 12-well
flat-bottom plates (Corning Inc., Corning, N.Y.) in complete RPMI 1640 (Sigma) containing 5% FCS, 20 µM
-mercaptoethanol, 20 mM HEPES, 2 mM L-glutamine, and antibiotics. To assess memory CTL
responses, mice were infected as described above and maintained for 2 to 26 weeks. Spleen cell suspensions were generated as described above
except for a brief exposure at 37°C to Tris-buffered 0.83% NH4Cl to lyse erythrocytes. The resulting lymphocytes were
cultured (107 cells per well) in complete RPMI 1640 at
37°C and 5% CO2, for 5 days in 12-well flat-bottom
plates in the presence of 3 × 105 mitomycin
C-treated, EHV-1 KyA-infected L-M cells (28). Stimulator cells were infected (EHV-1 KyA, multiplicity of infection of 10 for
18 h) to allow the expression of late viral gene products (38). Cytolytic activity was assessed in a standard 4-h
51Cr release assay in 96-well V-bottom plates (Nunc,
Denmark) to allow analysis of a range of effector-to-target ratios
against 104 51Cr-labeled, infected or
uninfected target cells. The percentage of specific lysis was
determined by using the formula [(A
B)/(C
B)] × 100, where A is
51Cr released by target cells incubated with effector cells
(experimental release), B is 51Cr released from
targets incubated in medium alone (spontaneous release), and
C is 51Cr released from targets incubated in 3%
acetic acid (maximum release). Each effector-to-target ratio was
assayed in triplicate. The spontaneous release never exceeded 20%, and
the variability between the values of specific lysis of triplicate
cultures did not exceed 5%.
Adoptive transfer of lymphocytes.
Donor immune lymphocytes
were obtained from the spleens of mice infected with EHV-1 KyA 2 weeks
previously. The lymphocytes were processed, restimulated in vitro for 5 days, and resuspended in RPMI 1640 without FCS at a concentration of
8 × 107 cells/ml. Recipient mice were given a
sublethal dose of 500 cGy of total-body
irradiation and infected
i.n. 1 h later with 1.5 × 106 PFU of EHV-1
RacL11. One to two hours following infection, recipients received
2 × 107 immune lymphocytes via tail vein injection.
Control animals received 2 × 107 nonimmune
splenocytes from uninfected mice. Four days following transfer, the
lungs were removed, and the titer of infectious EHV-1 RacL11 was
determined.
Selective depletion of T-lymphocyte subpopulations.
To
identify the functional T-lymphocyte subpopulation(s) in the in vitro
cytolytic assays and the in vivo protection assays, cultured
lymphocytes were first subjected to two rounds of antibody-dependent, complemented-mediated depletion (21). CD4+ T
cells were depleted with monoclonal antibody (MAb) RL-172 (rat immunoglobulin M [IgM] [15]) and rabbit complement
(Low-Tox M; Accurate Scientific, Westbury, N.Y.). CD8+ T
cells were depleted with the MAb 3.155 (rat IgM [45])
and complement. Depleted populations were resuspended in the original volume to avoid increasing the concentration of the remaining T cells.
The efficacy of depletion was determined by subsequent staining with
fluorescein isothiocyanate-conjugated anti-CD4 (GK1.5, rat IgG2b
[55]) or phycoerythrin-conjugated anti-CD8 (CT-CD8b, rat IgG2a; Caltag Laboratories, Burlingame, Calif.). Flow cytometric analysis was performed with a Profile II analyzer (Coulter, Hialeah, Fla.).
Statistical analysis.
The significance of differences in
virus recovery from immunized mice or from recipients of immune donor
cells and the appropriate control groups was determined by Student's
two-tailed t test (Mann-Whitney analysis of variance).
 |
RESULTS |
Infection of CBA mice with EHV-1.
To assess the susceptibility
of CBA mice to infection with EHV-1, groups of animals were infected in
the respiratory tract with 2 × 106 PFU of KyA or
1.5 × 106 RacL11 by i.n. inoculation, and the titers
of infectious virus were determined at different times p.i. The results
(Fig. 1) demonstrated that the levels of
both EHV-1 strains were highest at 2 days p.i. and steadily declined
thereafter to undetectable levels by day 6. Histological examination of
infected lungs revealed that inflammatory infiltration was evident by
day 3 p.i., with substantial consolidation involving up to 30% of
the lungs by day 5 of infection for KyA and greater than 50% of the
lungs for RacL11 (data not shown). In some experiments, mice infected
with RacL11 died 6 to 7 days p.i., while no animals died following KyA
infection. Lung consolidation was most severe when virus titers were at
their lowest, suggesting that severe pneumonia was independent of virus
levels in the lung.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of EHV-1 and RacL11 growth in the lungs of CBA
mice. CBA mice were infected i.n. with 2 × 106 PFU of
KyA or 1.5 × 106 PFU of RacL11 and on days 2 through
6; the lungs were removed and homogenized in a 3-ml tissue grinder. The
amount of infectious EHV-1 was determined by standard plaque titration
on RK monolayers as described in Materials and Methods. Each dot
represents the log PFU per lung determined from a single mouse. The
horizontal bars represent the mean log PFU per experimental group.
|
|
Assessment of EHV-1-specific cytolytic activity during primary
EHV-1 infection.
CBA mice were infected i.n. with 2 × 106 PFU of KyA, and on day 5 p.i. the CLN draining the
nasal turbinates and the MLN draining the lungs were removed and
cultured for 3 days to allow cytolytic activity to develop, as
demonstrated previously for other herpesviruses (14, 28, 42,
47). The results (Fig. 2)
demonstrated that EHV-1-specific CTL were present in the MLN by day
3 p.i., peaked by day 5, and diminished by day 7. In contrast,
little or no cytolytic activity was detected in the CLN at any time
during infection. This finding suggested that EHV-1-specific CTL
activity, elicited by the avirulent KyA strain, was compartmentalized
primarily to the MLN draining the lung, even though there was an
increase in cellularity in the CLN draining the nasal turbinates, the
initial site of virus replication (5) (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Cytolytic activity in the MLN and CLN. CBA mice were
infected intranasally with 2 × 106 PFU of KyA. On
days 3, 5, and 7 p.i., the MLN and CLN were removed, a single-cell
suspension was obtained, and the resulting LN cells were cultured for 3 days as described in Materials and Methods. Cytolytic activity was
measured in a standard 4-h 51Cr release assay using
mock-infected ( ) or KyA-infected ( ) L-M fibroblasts as targets.
Each effector-to-target (E:T) ratio was assayed in triplicate. The
spontaneous release never exceeded 20%, and the variability between
the values of specific lysis of triplicate cultures did not exceed
5%.
|
|
EHV-1-specific CTL activity is mediated by CD8+ T
cells.
The phenotype of the MLN-resident T-cell subpopulation
mediating cytolytic activity was assessed by selective depletion prior to assay. MLN lymphocytes were obtained 5 days p.i. with KyA, cultured
for 3 days in vitro, and depleted by treatment with MAb specific for
murine CD4 or CD8
in the presence of complement. Depletion of
CD4+ T cells had no effect on the cytolytic activity
observed, while the elimination of CD8+ lymphocytes from
this population abrogated EHV-1-specific CTL (Fig.
3). These results indicated that the
cytolytic activity is mediated exclusively by CD8+, class I
MHC-restricted T cells, although the formal demonstration of class I
MHC restriction was not possible due to the lack of allogeneic murine
cell lines susceptible to infection with EHV-1.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Abrogation of primary CTL activity by depletion of
CD8+ T lymphocytes in vitro. MLN were removed 5 days after
i.n. infection with 2 × 106 PFU of KyA, and a
single-cell suspension was obtained and cultured as described in
Materials and Methods. The resulting lymphocytes were either
nondepleted or depleted of CD4+ or CD8+ T
lymphocytes with specific antibody plus complement immediately prior to
assay as described in Materials and Methods. Flow cytometric analyses
of depleted cell populations revealed that the efficacy of CD4 and CD8
depletion was greater than 99%. Cytolytic activity was measured in a
standard 4-h 51Cr release assay using mock-infected ( )
or KyA-infected ( ) L-M fibroblasts as targets. Each
effector-to-target (E:T) ratio was assayed in triplicate. The
spontaneous release never exceeded 20%, and the variability between
the values of specific lysis of triplicate cultures did not exceed
5%.
|
|
Determination of EHV-1-specific memory CTL activity.
To
determine whether EHV-1-specific memory CTL activity was established
following infection, splenocytes from mice infected with strain KyA at
6, 16, and 26 weeks previously were restimulated for 5 days in vitro
with mitomycin C-treated, EHV-1-infected L-M cells. The results
demonstrated that EHV-1 infection generated a virus-specific memory CTL
response that was detected at all time points (Fig.
4). Importantly, a vigorous CTL response
was recalled as late as 26 weeks following a single i.n. inoculation of
the candidate vaccine strain, KyA (Fig. 4). As with the primary CTL
response, depletion of the CD8+ T-cell subpopulation
eliminated the cytolytic activity, while depletion of CD4+
T cells was without effect (Fig. 4), indicating that the cytolytic activity recalled by antigenic stimulation in vitro was also mediated by class I MHC-restricted, CD8+ T cells. These results
demonstrated that in addition to the generation of long-lived antibody
(16) and CD4+ T-cell (56) responses,
the attenuated KyA strain also generated a long-lived CD8+
T-cell response. Therefore, the candidate vaccine strain has the
ability to elicit all components of the acquired immune response that
are likely to be involved in controlling viral infections.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Memory CD8+ CTL isolated from the spleen
following KyA infection. CBA mice were infected i.n. with 2 × 106 PFU of KyA and at 6 weeks (A), 16 weeks (B), and 26 weeks (C) p.i., the spleens were removed and a single-cell suspension
was obtained as described in Materials and Methods; 107
splenocytes/well were restimulated for 5 days in vitro in the presence
of 3 × 105 KyA-infected, mitomycin C-treated L-M
fibroblasts as stimulators. Following in vitro restimulation, cytolytic
activity was measured in a standard 4-h 51Cr release assay
using mock-infected ( ) or KyA-infected ( ) L-M fibroblasts as
targets. Splenocytes isolated from CBA mice infected 4 weeks prior (D)
were either nondepleted and tested against mock-infected ( ) or
KyA-infected ( ) targets or depleted of CD4+ ( ) or
CD8+ ( ) T cells by specific antibody and complement
treatment immediately prior to cytolytic assay against KyA-infected
targets. Lysis of mock-infected targets by depleted populations never
exceeded that observed by nondepleted splenocytes (data not shown). In
all panels, each effector-to-target (E:T) ratio was assayed in
triplicate. The spontaneous release never exceeded 20%, and the
variability between the values of specific lysis of triplicate cultures
did not exceed 5%.
|
|
Adoptive transfer of protection by EHV-1-specific, restimulated
memory lymphocytes expressing cytolytic function.
Infection of
BALB/c mice with the nonpathogenic EHV-1 strain KyA results in
long-term protection against challenge with pathogenic EHV-1 strain
RacL11 (16). The present study confirmed that a similar
protective response was elicited in the CBA mouse model. Mice infected
with strain KyA were protected against infection with strain RacL11,
compared to age-matched control mice, as demonstrated by reduced viral
titers and faster clearance from the lungs (Fig. 5). Since viral clearance has been
associated with the presence of EHV-1-specific antibody and T-cell
responses, the contribution of the EHV-1-specific CD8+ T
cells was determined. To achieve this, donor mice were immunized by the
i.n. route with 2 × 106 PFU of KyA. Two weeks
following immunization, the spleens were removed and the splenocytes
were restimulated in vitro for 5 days. The donor cells, expressing high
levels of EHV-1-specific CTL activity, were selectively depleted of
CD4+ and/or CD8+ T cells immediately prior to
transfer into irradiated recipient mice infected 1 h previously
with 1.5 × 106 PFU of pathogenic RacL11. It was found
that 2 × 107 immune donor cells, treated with
complement alone, reduced markedly (>250-fold) the levels of RacL11
recovered from the lungs 4 days posttransfer compared to recipients of
nonimmune donor cells (Fig. 6). In
contrast, depletion of both CD4+ and CD8+ T
cells abrogated completely the protective capabilities of the transferred cells (Fig. 6). Surprisingly, depletion of either CD4+ or CD8+ T cells alone had no effect on the
levels of conferred protection (Fig. 6), suggesting that either each
subpopulation alone was protective or mechanisms independent of
CD4+ and CD8+ T cells were also present in the
cultures and were responsible for viral clearance. These results
indicated that while T cells activated in vitro are capable of reducing
EHV-1 RacL11 in the lungs of challenged mice, either T-cell
subpopulation, independently, was sufficient for the transfer of
protection.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 5.
Inoculation i.n. with the attenuated KyA strain is
protective against subsequent challenge with the pathogenic EHV-1
strain RacL11. Groups of CBA mice were either uninfected ( ) or
infected i.n. with 2 × 106 PFU of KyA ( ). Two
weeks following KyA infection, both groups of mice were infected i.n.
with 1.5 × 106 PFU of RacL11. On days 2 and 4 postchallenge, the lungs were removed and homogenized, and the amount
of infectious EHV-1 was determined by standard plaque titration as
previously described. Each dot represents the log PFU per lung
determined from a single mouse. The horizontal bars represent the mean
log PFU per experimental group.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6.
Adoptive transfer of immune lymphocytes into
RacL11-infected, irradiated recipient CBA mice. Immune lymphocytes for
transfer were isolated from the spleens of donor mice inoculated 2 weeks previously with 2 × 106 PFU of KyA. Donor
lymphocytes were restimulated in vitro for 5 days in the presence of
3 × 105 KyA-infected, mitomycin C-treated L-M
fibroblast stimulators. On the day of transfer, recipient mice were
given 500 cGy of total-body irradiation and were infected i.n. with
1.5 × 106 PFU of RacL11. Immune donor lymphocytes
were either left untreated, depleted in vitro of CD4+ or
CD8+ T cells, or depleted of both CD4+ and
CD8+ T cells immediately prior to transfer. Following in
vitro depletion, the remaining cells were transferred in a volume of
0.25 ml to recipient mice via tail vein injection. Control mice
received 2 × 107 nonimmune (Non-Imm) splenocytes. The
amount of infectious EHV-1 was determined by standard plaque titration
on RK monolayers as described in Materials and Methods. Each dot
represents the log PFU per lung determined from a single mouse. The
horizontal bars represent the mean log PFU per experimental group.
|
|
 |
DISCUSSION |
It has long been recognized that class I MHC-restricted,
CD8+ T cells play an important role in controlling acute
and chronic viral infections (46, 57, 58). Their ability to
recognize viral peptides presented in association with class I MHC
gives them a central role in surveillance for infected cells. In
experimental murine models of infection with the prototypical
alphaherpesvirus, herpes simplex virus type 1, a role for both class I
MHC-restricted, CD8+ T cells and class II MHC-restricted,
CD4+ T cells has been demonstrated (reviewed in reference
46). The relative importance of either subpopulation
is highly dependent on the site of infection, but both subpopulations
appear to be necessary for the optimal response to infection
(46). Studies of a variety of viral infections of the
respiratory tract have suggested a crucial role for CD8+
CTL in recovery from acute infection and protection against reinfection (1, 18, 29, 31, 44, 51). It is likely that this T-cell subpopulation plays a role in the immune response to EHV-1 infection in
the natural equine host, because EHV-1-specific, class I
MHC-restricted, CD8+ T cells have been isolated from the
peripheral blood of infected animals (4) and infiltrate in
high numbers into the infected lung (30). In the mouse model
of EHV-1 infection, a role for CD8+ T cells in controlling
infection in the lung was demonstrated by adoptive transfer studies
(7). However, no functional studies of this T-cell
subpopulation in the mouse have been reported.
In the present study, the primary and memory CD8+ CTL
responses to EHV-1 respiratory tract infection in a susceptible mouse strain were evaluated. It was demonstrated that upper respiratory tract
infection by the i.n. inoculation of CBA mice with the attenuated EHV-1
KyA strain resulted in the generation of cytolytic effectors in the
draining MLN during the acute phase of infection. Kinetic analysis of
the response revealed that CTL activity in the draining MLN peaked at 5 days p.i. and declined thereafter. This pattern is similar to the
response to other acute viral infections (28, 32, 48) and
corresponded well with the kinetics of viral clearance from the lungs.
Moreover, EHV-1 infection in the lung resulted in long-lived memory
EHV-1-specific CTL activity in the spleen, which could be detected in
infected mice at 26 weeks postimmunization by stimulating resting
memory CTL precursors with EHV-1-infected stimulator cells in culture.
In conjunction with the findings of previous studies of the immune
response to EHV-1 in mice (2, 7, 16, 37, 49, 52, 56), the
demonstration of class I MHC-restricted, EHV-1-specific CTL indicated
that all of the components of the acquired immune response identified
during the natural infection in equines have their counterpart in the
mouse model.
While EHV-1-specific CTL activity was readily detected in the MLN,
relatively little CTL activity was detected in the CLN at any time
during infection. This was surprising, since the CLN drains the nasal
turbinate region, where EHV-1 is known to replicate (5).
Therefore, the CTL response to EHV-1 was compartmentalized to the LN
draining the lung, which is the major site of infection. Compartmentalization of CTL effector function associated with respiratory viral infections has been described elsewhere (25, 26). Although EHV-1 replicates to slightly lower levels in the nasal turbinates than in the lungs, the kinetics of EHV-1 growth and
clearance from the tissue is almost identical to that observed in the
lungs (5). Therefore, lack of CTL activity due to a variation in the duration and extent of antigenic stimulation is an
unlikely explanation for the CTL compartmentalization. Furthermore, flow cytometric analyses of lymphoid cell populations isolated at 5 days p.i. revealed little difference in the percentage of CD8+ cells in the CLN and MLN. Routinely, the percentage of
CD8+ T cells in both lymphoid sites ranged from 22 to 25%.
It is possible that EHV-1-specific CTL are present in the CLN but at
frequencies too low to be detected in the assay used. An important
component of this assay is the target cell. Subsequent studies have
shown that the L-M cell line used in these assays has reduced
expression of H-2Dk (unpublished observation).
Because this class I MHC molecule may be an important restriction
element for EHV-1-specific CTL in CBA mice, the lower levels of its
expression would hinder the detection of that component of the response
restricted to H-2Dk. However, our recent studies
using an L2 mouse fibroblast that expresses both the
H-2Dk and the H-2Kk
molecules support the observation that significant differences in the
CTL response occur in the MLN versus the CLN in EHV-1-infected CBA
mice.
The demonstration of EHV-1-specific CTL activity in mice identifies a
potential weapon in the arsenal of responses directed against infection
but does not directly implicate this subpopulation in controlling
infection. While recent studies of influenza virus infection of mice
have clearly implicated cytolytic mechanisms as essential for
eradication of virus from the lung (53), direct evidence of
cytolytic activity as the principal mechanism against other respiratory
pathogens is lacking. Adoptive transfer of restimulated spleen cell
cultures expressing high levels of cytolytic function resulted in an
approximate 250-fold reduction of infectious RacL11 in the lungs of
irradiated, infected recipient mice. The depletion of both
CD4+ and CD8+ T cells abrogated totally the
ability of the transferred cells to mediate viral clearance.
Interestingly, the selective depletion of either T-cell subpopulation
alone had little effect. These results suggested that either
CD4+ or CD8+ T cells alone, or other, as yet
undefined components remaining in the activated spleen cell population,
were able to mediate the functions responsible for clearance of RacL11
from the lung. These results also clearly indicated that EHV-1-specific
CD4+ T cells were also restimulated in culture, presumably
by the processing and presentation of virion components or
infected-cell components by antigen-presenting cells present in the
spleen. The ability of CD4+ T cells to mediate protection
against viral pathogens in the absence of CD8+ T cells has
been observed previously (26, 43, 48). Although the
functions employed by CD4+ T cells in this model have not
yet been evaluated, the production of cytokine such as gamma interferon
(48) is a likely mechanism. It is clear, however, that
CD8+ T cells mediate their function through direct
interaction with infected cells in the lung (25), while
CD4+ T cells may be effective by more indirect interactions
(54). Future studies will address which effector functions,
whether cytolytic or cytokine mediated, are important for optimal viral clearance.
Although the adoptive transfer experiments do not conclusively
establish a role for the CD8+ T-cell subpopulation in
controlling EHV-1 infection in the mouse, other evidence does support
this contention. First, CD8+ T cells isolated from the
spleens of EHV-1-infected BALB/c mice and adoptively transferred into
recipient animals without further antigenic stimulation are more
effective than CD4+ T cells in controlling respiratory
infection (7). Second, analysis of the infiltrating cells
isolated from the lungs of EHV-1-infected CBA mice showed a high
proportion of CD8+ T cells in the infiltrate relative to
other lymphocyte subpopulations. These cells, when isolated directly
from the lung, express cytolytic function against EHV-1-infected target
cells (47a), suggesting they express direct cytolytic
function in situ.
The results described here and elsewhere (16, 56) indicate
that the attenuated EHV-1 strain KyA is able to induce a long-term protective response against challenge with pathogenic EHV-1 RacL11 in
the murine model. This protection was shown to be associated with
elevated levels of EHV-1-specific antibody and CD4+ T-cell
responses, and the present study has demonstrated for the first time
that a component of the response is cytolytic activity mediated by
EHV-1-specific CD8+ T lymphocytes. The ability to generate
and measure cytolytic activity and to transfer immune protection to
naive recipients should provide a valuable model to determine the
precise functions associated with protection and recovery from
respiratory EHV-1 infection. In addition, this model will be invaluable
in determining if specific EHV-1 proteins are capable of eliciting a
protective response without the inflammatory immunopathology commonly
associated with viral infection of the lung. Although the
identification of viral components that generate EHV-1-specific CTL in
CBA mice will not be directly applicable to the equine infection, basic information of this type may be important for the design and
engineering of a recombinant KyA vaccine. In this regard, initial
experiments indicate that the sole immediate-early protein and the
novel IR6 protein that is made in large quantities throughout infection are EHV-1 proteins that serve as CTL targets and thus should be considered in the design of candidate vaccine viruses.
 |
ACKNOWLEDGMENTS |
We thank Suzanne Zavecz for excellent technical assistance.
This study was supported in part by research grants AI 22001 (D.J.O.)
and NS 32464 (S.R.J.) from the National Institutes of Health and by
funds made available through Boehringer Ingleheim Vetmedica GmbH,
Ingleheim, Germany.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Louisiana State University Medical Center, School of Medicine in Shreveport, 1501 Kings Highway, Shreveport, LA
71130. Phone: (318) 675-5750. Fax: (318) 675-5764. E-mail: docall{at}lsumc.edu.
 |
REFERENCES |
| 1.
|
Ada, G. L., and P. D. Jones.
1986.
The immune response to influenza infection.
Curr. Top. Microbiol. Immunol.
128:1-54[Medline].
|
| 2.
|
Alber, D. G.,
J. Greensill,
R. A. Killington, and A. Stokes.
1995.
Role of T-cells, virus neutralising antibodies and complement-mediated antibody lysis in the immune response against equine herpesvirus type-1 (EHV-1) infection of C3H (H-2k) and BALB/c (H-2d) mice.
Res. Vet. Sci.
59:205-213[Medline].
|
| 3.
|
Allen, G. P., and J. T. Bryans.
1986.
Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections.
Prog. Vet. Microbiol. Immunol.
2:78-144[Medline].
|
| 4.
|
Allen, G. P.,
M. Yeargan,
L. R. R. Costa, and R. Cross.
1995.
Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response in horses infected with equine herpesvirus 1.
J. Virol.
69:606-612[Abstract].
|
| 5.
|
Awan, A. R.,
Y.-C. Chong, and H. J. Field.
1990.
The pathogenesis of equine herpesvirus type 1 in the mouse: a new model for studying host responses to the infection.
J. Gen. Virol.
71:1131-1140[Abstract/Free Full Text].
|
| 6.
|
Awan, A. R.,
J. S. Gibson, and H. J. Field.
1991.
A murine model for studying EHV-1 induced abortion.
Res. Vet. Sci.
51:94-99[Medline].
|
| 7.
|
Azmi, M., and H. J. Field.
1993.
Cell-mediated antiviral response to equine herpesvirus type 1 demonstrated in a murine infection model by means of adoptive transfer of immune cells.
J. Gen. Virol.
74:275-280[Abstract/Free Full Text].
|
| 8.
|
Bagust, T. J.
1971.
The equine herpesviruses.
Vet. Bull.
41:79-91.
|
| 9.
|
Bell, C. W.,
D. B. Boyle, and J. M. Whalley.
1990.
Transcript analysis of the equine herpesvirus glycoprotein B gene homologue and its expression by a recombinant vaccinia virus.
J. Gen. Virol.
71:1119-1129[Abstract/Free Full Text].
|
| 10.
|
Bryans, J. T., and G. P. Allen.
1986.
Equine viral rhinopneumonitis.
Rev. Sci. Tech. Off. Int. Epizoot.
5:837-847.
|
| 11.
|
Burki, F.,
W. Rofsmanith,
N. Nowotny,
C. Pallan,
K. Mostl, K., and H. Lussy.
1990.
Viremia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses.
Vet. Q.
12:80-86[Medline].
|
| 12.
|
Burrows, R.,
D. Goodridge, and M. S. Denyer.
1984.
Trials of an inactivated equid herpesvirus-1 vaccine: challenge with a subtype-1 virus.
Vet. Res.
114:369-374.
|
| 13.
|
Carrol, C. L., and H. A. Westbury.
1985.
Isolation of equine herpesvirus type 1 from the brain of a horse affected with paresis.
Aust. Vet. J.
62:345-346[Medline].
|
| 14.
|
Carter, V. C.,
P. A. Schaffer, and S. S. Tevethia.
1981.
The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.
J. Immunol.
126:1655-1660[Abstract].
|
| 15.
|
Ceredig, R.,
J. W. Lowenthal,
M. Nabholz, and H. R. MacDonald.
1985.
Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells.
Nature
314:98-100[Medline].
|
| 16.
|
Colle, C. F., III,
E. B. Tarbet,
W. D. Grafton,
S. R. Jennings, and D. J. O'Callaghan.
1996.
Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers in mice challenged with a pathogenic strain RacL.
Virus Res.
43:111-124[Medline].
|
| 17.
|
Crabb, B. S., and M. J. Studdert.
1995.
Equine herpesvirus 4 (equine rhinopneumonitis virus) and 1 (equine abortion virus).
Adv. Virus Res.
45:153-190[Medline].
|
| 18.
|
de Waal, L. P.,
W. M. Kast,
R. W. Melvoid, and C. J. M. Melief.
1983.
Regulation of the cytotoxic T lymphocyte response against Sendai virus analyzed with H-2 mutants.
J. Immunol.
130:1090-1096[Medline].
|
| 19.
|
Ellis, J. A.,
J. R. Bogdan,
E. W. Kanara,
P. S. Morley, and D. M. Haines.
1995.
Cellular and antibody responses to equine herpesviruses 1 and 4 following vaccination of horses with modified-live and inactivated viruses.
J. Am. Vet. Med. Assoc.
206:823-832[Medline].
|
| 20.
|
Ellis, J. A.,
E. Steeves,
A. K. Wright,
J. R. Bogdan,
W. C. Davis,
E. W. Kanara, and D. M. Haines.
1997.
Cell-mediated cytolysis of equine herpesvirus-infected cells by leukocytes from young vaccinated horses.
Vet. Immunol. Immunopathol.
57:201-214[Medline].
|
| 21.
|
Flyer, D. C.,
R. W. Anderson, and S. S. Tevethia.
1982.
Lyt phenotype of H-2b CTL effectors and precursors specific for the SV40 transplantation rejection antigen.
J. Immunol.
129:2368-2371[Abstract].
|
| 22.
|
Grandell, R. A.,
R. E. Mock, and T. F. Lock.
1980.
Vaccination of pregnant ponies against equine rhinopneumonitis.
Am. J. Vet. Res.
41:994-996[Medline].
|
| 23.
|
Guo, P. I.,
S. Goebel,
M. E. Perkus,
J. Taylor,
E. Norton,
G. Allen,
B. Languet,
P. Desmettre, and E. Paoletti.
1990.
Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity.
J. Virol.
64:2399-2406[Abstract/Free Full Text].
|
| 24.
|
Hannant, D.,
D. M. Jessett,
T. O'Neill,
C. A. Dolby,
R. F. Cook, and J. A. Mumford.
1993.
Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain.
Res. Vet. Sci.
54:299-305[Medline].
|
| 25.
|
Hou, S., and P. C. Doherty.
1995.
Clearance of Sendai virus by CD8+ T cells requires direct targeting to virus-infected epithelium.
Eur. J. Immunol.
25:111-116[Medline].
|
| 26.
|
Hou, S.,
P. C. Doherty,
M. Zijlstra,
R. Jaenisch, and J. M. Katz.
1992.
Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells.
J. Immunol.
149:1319-1325[Abstract].
|
| 27.
|
Jackson, T. A., and J. W. Kendrick.
1971.
Paralysis of horses associated with equine herpesvirus 1 infection.
J. Am. Vet. Med. Assoc.
158:1351-1357[Medline].
|
| 28.
|
Jennings, S. R.,
R. H. Bonneau,
P. M. Smith,
R. M. Wolcott, and R. Chervenak.
1991.
CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice.
Cell. Immunol.
133:234-252[Medline].
|
| 29.
|
Kast, W. M.,
A. M. Bronkhorst,
L. P. de Waal, and C. J. M. Melief.
1986.
Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated, a model for MHC-disease associations.
J. Exp. Med.
164:723-738[Abstract/Free Full Text].
|
| 30.
|
Kydd, J. H.,
D. Hannant, and J. A. Mumford.
1996.
Residence and recruitment of leucocytes to the equine lung after EHV-1 infection.
Vet. Immunol. Immunopathol.
52:15-26[Medline].
|
| 31.
|
Lukacher, A. E.,
V. L. Braciale, and T. J. Braciale.
1984.
In vivo effector function of influenza virus-specific T lymphocytes is highly specific.
J. Exp. Med.
160:814-826[Abstract/Free Full Text].
|
| 32.
|
Lynch, F.,
P. C. Doherty, and R. Ceredig.
1989.
Phenotypic and functional analysis of the cellular response in regional lymphoid tissue during an acute virus infection.
J. Immunol.
142:3592-3598[Abstract].
|
| 33.
|
Matsumura, T.,
T. Kondo,
S. Sugita,
A. M. Damiani,
D. J. O'Callaghan, and H. Imagawa.
1998.
An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses.
Virology
242:68-79[Medline].
|
| 34.
|
Matsumura, T.,
D. J. O'Callaghan,
T. Kondo, and M. Kamada.
1996.
Lack of virulence of the murine fibroblast adapted strain, Kentucky A (KyA), of equine herpesvirus type 1 (EHV-1) in young horses.
Vet. Microbiol.
48:353-365[Medline].
|
| 35.
|
Meyer, H.,
P. Thein, and P. Hubert.
1987.
Characterization of two equine herpesvirus (EHV) isolates associated with neurological disorders in horses.
Zentbl. Veterinaermed. Reihe B
34:545-548.
|
| 36.
|
Mumford, J. A.,
D. A. Hannant,
D. M. Jessett,
T. O'Neill,
K. C. Smith, and E. N. Ostlund.
1995.
Abortigenic and neurological disease caused by infection with equid herpesvirus-1, p. 261-275.
In
H. Nakajima, and W. Plowright (ed.), Proceedings of the 7th International Conference of Equine Infectious Diseases. R&W Publisher, Newmarket, United Kingdom.
|
| 37.
|
Neubauer, A.,
M. Beer,
C. Brandmuller,
O.-R. Kaaden, and N. Osterrieder.
1997.
Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection.
Virology
239:36-45[Medline].
|
| 38.
|
O'Callaghan, D. J., and N. Osterrieder.
1998.
Equine herpesviruses.
In
R. G. Webster, and A. Granoff (ed.), Encyclopedia of virology, 2nd ed., in press Academic Press, Harcourt Brace & Company, Publishers, San Diego, Calif.
|
| 39.
|
Osterrieder, N.,
R. Wagner,
C. Brandmuller,
P. Schmidt,
H. Wolf, H., and O.-R. Kaaden.
1995.
Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).
Virology
208:500-510[Medline].
|
| 40.
|
Osterrieder, N.,
R. Wagner,
M. Pfeffer, and O.-R. Kaaden.
1994.
Expression of equine herpesvirus type 1 glycoprotein gp14 in Escherichia coli and in insect cells: a comparative study on protein processing and humoral immune responses.
J. Gen. Virol.
75:2041-2046[Abstract/Free Full Text].
|
| 41.
|
Perdue, M. L.,
M. C. Kemp,
C. C. Randall, and D. J. O'Callaghan.
1974.
Studies of the molecular anatomy of the L-M strain of equine herpesvirus type 1: protein of the nucleocapsid and intact virion.
Virology
59:201-216[Medline].
|
| 42.
|
Pfizenmaier, K.,
H. Jung,
A. Starzinski-Powitz,
M. Rollinghof, and H. Wagner.
1977.
The role of T cells in anti-herpes simplex virus immunity. I. Induction of antigen-specific cytotoxic T lymphocytes.
J. Immunol.
119:939-944[Abstract/Free Full Text].
|
| 43.
|
Polic, B.,
S. Jonjic,
I. Pavic,
I. Crnkovic,
I. Zorica,
H. Hengel,
P. Lucin, and U. H. Koszinowski.
1996.
Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo.
J. Gen. Virol.
77:217-225[Abstract/Free Full Text].
|
| 44.
|
Reddehase, M. J.,
W. Mutter,
K. Munch,
H.-J. Buhring, and U. H. Koszinowski.
1987.
CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity.
J. Virol.
61:3102-3108[Abstract/Free Full Text].
|
| 45.
|
Sarmiento, M.,
A. L. Glasebrook, and F. W. Fitch.
1980.
IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.
J. Immunol.
125:2665-2672[Abstract].
|
| 46.
|
Schmid, D. S., and B. T. Rouse.
1992.
The role of T cell immunity in control of herpes simplex virus.
Curr. Top. Microbiol. Immunol.
179:57-74[Medline].
|
| 47.
|
Sinickas, V. G.,
R. B. Ashman, and R. V. Blanden.
1985.
The cytotoxic response to murine cytomegalovirus. II. In vitro requirements for generation of cytotoxic T cells.
J. Gen. Virol.
66:757-765[Abstract/Free Full Text].
|
| 47a.
| Smith, P. M. Unpublished data.
|
| 48.
|
Smith, P. M.,
R. M. Wolcott,
R. Chervenak, and S. R. Jennings.
1994.
Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon Interferon- (IFN- ).
Virology
202:76-88[Medline].
|
| 49.
|
Stokes, A.,
D. G. Alber,
R. S. Cameron,
R. N. Marshall,
G. P. Allen, and R. A. Killington.
1996.
The production of a truncated form of baculovirus expressed EHV-1 glycoprotein C and its role in protection of C3H (H-2Kk) mice against virus challenge.
Virus Res.
44:97-109[Medline].
|
| 50.
|
Stokes, A.,
R. S. Cameron,
R. N. Marshall, and R. A. Killington.
1997.
High level expression of equine herpesvirus 1 glycoproteins D and H and their role in protection against virus challenge in the C3H (H-2Kk) murine model.
Virus Res.
50:159-173[Medline].
|
| 51.
|
Taylor, P. M., and B. A. Askonas.
1986.
Influenza nucleoprotein-specific cytotoxic T cell clones are protective in vivo.
Immunology
58:417-420[Medline].
|
| 52.
|
Tewari, D.,
J. M. Whalley,
D. N. Love, and H. J. Field.
1994.
Characterization of immune responses to baculovirus-expressed equine herpesvirus type 1 glycoproteins D and H in a murine model.
J. Gen. Virol.
75:1735-1741[Abstract/Free Full Text].
|
| 53.
|
Topham, D. J.,
R. A. Tripp, and P. C. Doherty.
1997.
CD8+ T cells clear influenza virus by perforin or Fas-dependent processes.
J. Immunol.
159:5197-5200[Abstract].
|
| 54.
|
Topham, D. J.,
R. A. Tripp,
S. R. Sarawar,
M. Y. Sangster, and P. C. Doherty.
1996.
Immune CD4+ T cells promote the clearance of influenza virus from major histocompatibility complex class II / respiratory epithelium.
J. Virol.
70:1288-1291[Abstract].
|
| 55.
|
Wilde, D. B.,
P. Marrack,
J. Kappler,
D. P. Dialynas, and F. W. Fitch.
1983.
Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines.
J. Immunol.
131:2178-2183[Abstract].
|
| 56.
| Zhang, Y., P. M. Smith, E. B. Tarbet, N. Osterrieder, S. R. Jennings, and D. J. O'Callaghan.
Protective immunity against equine herpesvirus type 1 (EHV-1) infection
in mice induced by recombinant EHV-1 gD. Virus Res., in press.
|
| 57.
|
Zinkernagel, R. M.
1993.
Immunity to viruses, p. 1211-1250.
In
W. E. Paul (ed.), Fundamental immunology, 3rd ed. Raven Press, Ltd., New York, N.Y.
|
| 58.
|
Zinkernagel, R. M., and P. C. Doherty.
1979.
MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness.
Adv. Immunol.
27:51-177[Medline].
|
J Virol, July 1998, p. 5366-5372, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Smith, P. M., Kahan, S. M., Rorex, C. B., von Einem, J., Osterrieder, N., O'Callaghan, D. J.
(2005). Expression of the Full-Length Form of gp2 of Equine Herpesvirus 1 (EHV-1) Completely Restores Respiratory Virulence to the Attenuated EHV-1 Strain KyA in CBA Mice. J. Virol.
79: 5105-5115
[Abstract]
[Full Text]
-
Huang, Y., Babiuk, L. A., van Drunen Littel-van den Hurk, S.
(2005). Immunization with a bovine herpesvirus 1 glycoprotein B DNA vaccine induces cytotoxic T-lymphocyte responses in mice and cattle. J. Gen. Virol.
86: 887-898
[Abstract]
[Full Text]
-
Soboll, G., Whalley, J. M., Koen, M. T., Allen, G. P., Fraser, D. G., Macklin, M. D., Swain, W. F., Lunn, D. P.
(2003). Identification of equine herpesvirus-1 antigens recognized by cytotoxic T lymphocytes. J. Gen. Virol.
84: 2625-2634
[Abstract]
[Full Text]
-
Smith, P. M., Zhang, Y., Grafton, W. D., Jennings, S. R., O'Callaghan, D. J.
(2000). Severe Murine Lung Immunopathology Elicited by the Pathogenic Equine Herpesvirus 1 Strain RacL11 Correlates with Early Production of Macrophage Inflammatory Proteins 1alpha , 1beta , and 2 and Tumor Necrosis Factor Alpha. J. Virol.
74: 10034-10040
[Abstract]
[Full Text]
-
Del Piero, F., Wilkins, P. A., Timoney, P. J., Kadushin, J., Vogelbacker, H., Lee, J. W., Berkowitz, S. J., La Perle, K. M. D.
(2000). Fatal Nonneurological EHV-1 Infection in a Yearling Filly. Vet Pathol
37: 672-676
[Abstract]
[Full Text]
-
Del Piero, F.
(2000). Diagnosis of Equine Arteritis Virus Infection in Two Horses by Using Monoclonal Antibody Immunoperoxidase Histochemistry on Skin Biopsies. Vet Pathol
37: 486-487
[Abstract]
[Full Text]